Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

BHA issues warning over products containing altrenogest
BHA is carrying out further work to understand the implications of this issue in Europe. 

Trace levels of anabolic steroids found in some products 

The British Horseracing Authority (BHA) is making vets and trainers aware of an international issue regarding products that contain altrenogest.

Trace levels of the anabolic steroids trenbolone and/or trendione have been detected in products containing altrenogest, which is commonly referred to by its trade name, Regumate.

Racing Victoria (Australia) has advised trainers to immediately cease using such products and further investigations are now underway.

In the UK, one such product is licensed for use in horses - Regumate Equine 2.2mg/ml Oral Solution for Horses (MSD Animal Health).

After discussions with the European manufacturer, BHA said it can confirm that the product distributed in the UK is reportedly sourced from a separate location to the products that are currently under investigation.

However, in light of the international situation, BHA is strongly advising trainers to be cautious if using altrenogest in racing thoroughbreds.

The BHA published Detection Time for altrenogest is 288 hours (15 days). In contrast, a 24-hour withdrawal from racing is recommended in Australia for mares and fillies receiving oral altrenogest.

BHA is carrying out further work to understand the implications of this issue in Europe.  

 

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
Free webinar explores congenital heart disease in dogs

A free webinar is to provide veterinary professionals, dog breeders and pet owners an new insights into congenital heart disease.

Chris Linney, a cardiology specialist and Veterinary Cardiovascular Society (VSC) member, will present the webinar from 7.00pm to 8.30pm on Wednesday, 12 November.

Dr Linney will explore the types, causes and clinical presentation of congenital heart conditions. This will include diagnostic approaches, treatment pathways and emerging research opportunities.

The session is the third to be organised by The Kennel Club, with the VCS, following an introductory webinar and a talk on acquired heart disease. Dr Linney's webinar consists of a one-hour presentation, followed by a 30-minute question and answer session.

Dr Linney said: "This webinar will be an opportunity to deepen understanding - not just of the diseases themselves, but of how breeders, vets and owners can work together to support affected dogs and improve outcomes for future generations."

Click here to register for the webinar.